Compare GSK plc (GSK) vs Rivian Automotive, Inc. (RIVN) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Rivian stock trades at $16.91, down 3.37% on the day, as the EV maker continues its transition toward profitability. Recent earnings beats and the upcoming R2 vehicle launch provide optimism, though negative cash flow and substantial losses remain concerns. Technical indicators show a bullish trend with support at $16 and resistance at $18-19, while analyst consensus favors a buy rating with a $19.22 price target.

The investment case hinges on Rivian's ability to scale production and achieve profitability, with the R2 launch representing a potential inflection point. Key risks include ongoing cash burn, competitive pressures, and execution challenges in a capital-intensive industry. Upside potential exists if the company can demonstrate sustainable margin improvement and demand strength for new models.